NYSE$ELAN
Elanco Animal Health Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Elanco's Q2 2024 financial performance reflected revenue growth, strategic progress, and updated financial guidance, excluding the Aqua divestiture.
Elanco reported Q2 2024 financial results with revenue of $1,184 million. The company reported a net loss of $50 million, but adjusted net income was $147 million. Adjusted EBITDA was $275 million, representing 23.2% of revenue. The company has raised its full-year revenue guidance and maintained its adjusted EBITDA guidance, excluding the Aqua divestiture.
- Revenue for the second quarter of 2024 was $1,184 million.
- Reported net loss was $50 million, while adjusted net income reached $147 million.
- Adjusted EBITDA stood at $275 million, which is 23.2% of revenue.
- The sale of the aqua business was completed in July, leading to a $1.2 billion debt paydown in Q3 2024.
Headline financials
Revenue & EPS history
Elanco · Revenue · Quarterly
$1.18B
Revenue by segment
Elanco · $1.58B total across 5 segments · Q3 2023
- Farm Animal$561M—35.6%
- Pet Health$495M+5.1%31.4%
- Cattle$242M+3.9%15.4%
- Poultry$184M+15.7%11.7%
- Swine$93M+10.7%5.9%
Forward guidance
Elanco has provided financial guidance for the third quarter and updated financial guidance for the full year 2024, reflecting the expected contribution from Bovaer and Zenrelia and the removal of the aqua business.
Tailwinds
- Revenue between $4.41 billion and $4.46 billion.
- Organic constant currency revenue growth of 3% to 4%.
- Adjusted EBITDA of $900 million to $940 million.
- Adjusted EPS of $0.88 to $0.96.
- Lower interest expense due to debt paydown.
Headwinds
- Headwind of approximately $30 million from the unfavorable impact of foreign exchange rates.
- Higher manufacturing losses expected.
- Increased investment in product launches in the second half of the year.
- Aqua business divestiture reduces revenue, adjusted EBITDA and adjusted EPS.
- Financial guidance reflects foreign currency exchange rates as of the beginning of August.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+2.0%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+1.1%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+27.2%
Q1 2024
Best reaction
-16.3%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +13.9% | -5.6% | +2.6% | |
| Q4 2025 | +7.3% | +6.7% | -0.7% | |
| Q3 2025 | -4.2% | -1.0% | -2.7% | |
| Q1 2025 | +26.2% | +34.8% | +46.2% | |
| Q4 2024 | -3.7% | +0.5% | -2.7% | |
| Q3 2024 | +9.4% | +9.8% | -2.8% | |
| Q2 2024 | +5.3% | +12.6% | +21.9% | |
| Q1 2024 | +27.2% | +25.7% | +34.7% | |
| Q4 2023 | +0.5% | -2.1% | -1.2% | |
| Q3 2023 | +15.9% | +14.1% | +36.4% | |
| Q2 2023 | +7.0% | +4.5% | +2.7% | |
| Q1 2023 | -3.8% | -8.4% | -0.1% | |
| Q4 2022 | -6.9% | -11.0% | -33.1% | |
| Q3 2022 | -10.3% | +0.4% | -6.7% | |
| Q2 2022 | -1.6% | +3.3% | -23.9% | |
| Q1 2022 | -7.9% | -6.4% | +1.5% | |
| Q4 2021 | +8.2% | +12.4% | +3.3% | |
| Q3 2021 | +1.2% | +0.3% | -14.3% | |
| Q2 2021 | -16.3% | -12.3% | -4.2% | |
| Q1 2021 | +3.8% | +3.4% | +10.1% | |
| Q4 2020 | +2.8% | +9.0% | -9.8% | |
| Q3 2020 | -4.7% | -8.0% | -9.8% | |
| Q2 2020 | +11.7% | +17.3% | +37.7% | |
| Q1 2020 | -13.5% | -12.9% | +3.6% | |
| Q4 2019 | -0.7% | -1.4% | -42.5% | |
| Q3 2019 | -1.9% | -3.1% | -1.2% | |
| Q2 2018 | -4.8% | -1.3% | -4.6% | |
| Q2 2019 | -4.8% | -1.3% | -4.6% | |
| Q1 2019 | +6.1% | +3.9% | +4.1% | |
| Q4 2018 | -2.4% | -1.7% | -2.7% | |
| Q3 2018 | +3.7% | +3.7% | -1.9% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro